ロード中...
Anti-CD20 monoclonal antibodies: historical and future perspectives
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ferrata Storti Foundation
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2805725/ https://ncbi.nlm.nih.gov/pubmed/19773256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2008.001628 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|